Dibunate (also known as Becantex, Becantyl, Linctussal, L-1633, and described as the 2,6-isomer or the 2,7-isomer) is an antitussive oral medication that was used in many counties all over the world. The current marketing status of the drug is unknown and is supposed to be "discontinued".

Butamirate (or brospamin) is a medicine used for the symptomatic treatment of non-productive (dry) cough. Butamirate is centrally acting cough suppressant which is neither chemically nor pharmacologically related to opium alkaloids. In addition to its antitussive effect, Butamirate also decreases the airway resistance. Butamirate is rapidly and completely absorbed after oral administration. Maximum concentration is reached within 9 hours with sustain release tablet. Butamirate is extremely protein bound and Plasma elimination half-life is about 13 hours. Butamirate is indicated in acute cough of any etiology, pre and post operative cough sedation for surgical procedure and bronchoscopy. Butamirate is well tolerated. In rare cases, skin rash, nausea, diarrhea, dizziness have been reported.They disappear after reduction of the dosage or discontinuation of the drug.

Fedrilate is a mucolytic drug. It was patented in 1963 and claimed to have a noteworthy anti-tussive activity.

Droxypropine belongs to the cough suppressant.

Letosteine is an expectorant. It dissolves bronchial mucus and reduces respiratory inflammation symptoms. Letosteine and ambroxol hydrochloride provided equivalent efficacy and safety in the treatment of sputum thickening and expectoration difficulty due to either acute or chronic respiratory diseases. Treatment with letosteine leads to a significant increase in the rate of regression of thoracic symptomatology and a faster, more substantial reduction in fever in children suffering from acute bronchitis. Letosteine had antioxidant activity. It may have a therapeutic application in preventing oxidative tissue injury damage induced by the respiratory burst. In a series of 37 patients, two experienced gastralgia and vomiting, severe enough to stop therapy. In another series of 40 patients, five had gastralgia and nausea, requiring withdrawal of therapy in three.

Levoverbenone or (1S)-(−)-Verbenone is an enantiomer of verbenone, a bicyclic monoterpene ketone, naturally occurring in insect pheromones, and in certain plant essential oils. It exerts acaricidal activity against Dermatophagoides spp. and Tyrophagus putrescentiae. In addition it acts as an anticolvunsant in rodent models. Levoverbenone is expected to be an expectorant.

Thebacon (dihydrocodeinone enol acetate, trade name Acedicon) is semisynthetic opioid analgetic and antitussive compound. Boehringer-Ingelheim merketed Acedicon for the treatment of cough. Thebacon is a Schedule I drug, that has not got approved use in US.

Acetyldihydrocodeine, a narcotic opiate derivative that was used in Germany as an analgesic. This drug has never been marketed in the USA.

Meprotixol is a thiaxanthene derivative. Meprotixol revealed a potent antitussive activity. It has slight central depressive effect. Meprotixol reduces the spontaneous motor activity of mice, but its potency is negligible in comparison with those of neuroleptics such as chlorpromazine and chlorprothixene. Meprotixol in suitable doses reduces the quantity of barbiturate required to secure anesthesia. Meprotixol showed a potent broncho-spasmolytic effect against 5-hydroxytryptamine spasms in guinea pigs. This compound has a marked inhibitory effect against various forms of edema and exudation in the granuloma pouch, though the inhibition of granuloma formation was only slight. Phenylbutazone seemed to be more effective than meprotixol in the treatment of rheumatic disease.

Tipepidine (INN) also known as tipepidine hibenzate (JAN), is a synthetic, non-opioid antitussive and expectorant of the thiambutene class. The drug was discovered in the 1950s, and was developed in Japan in 1959. It is used as the hibenzate and citrate salts. The safety of tipepidine in children and adults has already been established. It is reported that tipepidine inhibits G-protein-coupled inwardly rectifying potassium (GIRK)-channel currents. The inhibition of GIRK channels by tipepidine is expected to modulate the level of monoamines in the brain. Tipepidine can improve attention deficit/hyperactivity disorder (ADHD) symptoms by modulating monoaminergic neurotransmission through the inhibition of GIRK channels. Tipepidine also is being investigated in depression, obsessive-compulsive disorder, and attention-deficit hyperactivity disorder (ADHD). As it acts on the central nervous system, overdose can cause altered mental status and other neurological symptoms; however, there have been few reports of tipepidine intoxication, including six cases in children and no cases in adults.